Catalyst Pharmaceuticals (CPRX) Cash from Operations (2010 - 2026)

Catalyst Pharmaceuticals has reported Cash from Operations for 17 years, with the latest figure at 59587000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 0.76% year-over-year to 59587000.0; the trailing twelve-month figure through Mar 2026 stood at 208214000.0 (down 22.29% YoY), and the FY2025 full-year result was 208670000.0, down 12.98% from the prior year.
• Cash from Operations for Q1 2026 stood at 59587000.0, up from 44891000.0 in the prior quarter.
• The five-year high for Cash from Operations was 72871000.0 in Q3 2024, with the low at 8478000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 45159529.41 across 5 years, with a median of 44891000.0 in 2025.
• Annual changes were most pronounced in 2024 — Cash from Operations soared 164.5% — and 2025, when it slumped 55.49%.
• Catalyst Pharmaceuticals' Cash from Operations stood at 40077000.0 in 2022, then surged by 38.85% to 55648000.0 in 2023, then rose by 27.37% to 70877000.0 in 2024, then sank by 36.66% to 44891000.0 in 2025, then jumped by 32.74% to 59587000.0 in 2026.
• The last three Cash from Operations figures came in at 59587000.0 (Q1 2026), 44891000.0 (Q4 2025), and 32438000.0 (Q3 2025), per Business Quant data.